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Abstract 
The non-obese diabetic (NOD) mouse develops spontaneous type 1 diabetes, with some 
features of disease that are very similar to the human disease. However, a proportion of NOD 
mice are naturally-protected from developing diabetes, and currently studies characterising this 
cohort are very limited. Here, using both immunofluorescence and multi-parameter flow 
cytometry we focus on the pancreatic islet morphology and immune infiltrate observed in 
naturally-protected NOD mice. We show that naturally-protected NOD mice are characterised 
by an increased frequency of insulin-containing, smaller sized, pancreatic islets. Although mice 
remain diabetes free, florid immune infiltrate remains. However, this immune infiltrate is 
skewed towards a regulatory phenotype in both T and B-cell compartments. Pancreatic islets 
have an increased frequency of IL-10 producing B cells and associated cell surface markers. 
Resident memory CD69+CD8+ T cells show a significant shift towards reduced CD103 
expression, while CD4+ T cells have increased FoxP3+CTLA4+ expression. These data indicate 
that naturally-protected NOD mice have a unique islet signature and provide new insight into 
regulatory mechanisms within pancreatic islets.  
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Introduction 
Type 1 diabetes is an organ-specific autoimmune disease characterized by immune-mediated 
beta-cell destruction in pancreatic islets, which results in deficient insulin production. Similar 
to humans, Non Obese Diabetic (NOD) mice develop spontaneous type 1 diabetes. However, 
in NOD mouse colonies worldwide, approximately 20% (or more) of NOD mice remain 
normoglycemic and ‘protected’ from diabetes, despite their genetic predisposition (1). Few 
studies have been done to discover the mechanism of this natural protection. Recently, we have 
dissected the B-cell functionality in naturally-protected NOD mice, highlighting an increased 
IL-10-producing B-cell frequency and enhanced response to dendritic cells, compared to NOD 
mice that have developed diabetes (2). Furthermore, it has been suggested that B cells, 
specifically anergic CD40+IL-10-producing B cells, found in the pancreatic islets of long term 
normoglycemic mice (protected) (3), may confer this natural protection. Currently, the 
phenotype and function of CD4+ and CD8+ T cell populations in naturally-protected NOD mice 
is unexplored. 
Pancreatic islets have a dynamic tissue microenvironment, in which immune cells 
communicate to drive beta cell destruction. This is complicated by cellular and kinetic 
heterogeneity in both mouse and human pancreatic islets, including the rate of beta cell 
destruction. The aim of this study was to investigate the characteristics and heterogeneity of 
the islets in naturally-protected NOD mice, including the immune infiltrate.  This knowledge 
may provide insight into disease heterogeneity in humans, as not all at-risk individuals develop 
type 1 diabetes.  
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Research Design and Methods 
Mice 
Female NOD/Caj mice, originally from Yale University, were bred in-house at Cardiff 
University. All mice received water, irradiated food ad libitum and were housed in specific 
pathogen-free isolators or scantainers, with a 12h dark/light cycle, at Cardiff University. All 
animal experiments were approved by Cardiff University ethical review process and conducted 
under United Kingdom Home Office license in accordance with United Kingdom Animals 
(Scientific Procedures) Act, 1986 and associated guidelines. Diabetes conversion rates for 
Cardiff University can be found in (4) with approximately 80% incidence in females by 30 
weeks, with a median incidence at 19 weeks old. NOD female incidence at other institutions 
or companies can vary; e.g. at Jackson laboratories incidence is approximately 90% incidence 
by 30 weeks of age, with a median female onset at 18 weeks.  
Diabetes Incidence 
Mice were monitored weekly for glycosuria (Bayer Diastix) from 12 weeks of age. Following 
2 positive glycosuria measurements, blood glucose levels were tested and if greater than 
13.9mmol/L, mice were diagnosed as diabetic. NOD mice that were 35 weeks of age or older 
and had never tested positive for glycosuria were considered to be protected from diabetes, as 
the incidence of diabetes after this age is very low.  
Islet preparation 
Pancreata were inflated with collagenase P solution (1.1mg/ml) (Roche, Welwyn Garden City, 
UK) in HBSS (with Ca2+ and Mg2+) via the common bile duct, followed by collagenase 
digestion with shaking at 37°C for 10min. Islets were isolated by Histopaque density 
centrifugation (Sigma-Aldrich, Dorset, UK), and hand-picked under a dissecting microscope. 
For flow cytometric analysis islets were then trypsinized to generate a single cell suspension. 
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Islet cells were rested at 37°C 5% CO2 in IMDM (supplemented with 5% fetal bovine serum 
(FBS), 2mM L-glutamine, 100U/mL Penicillin, 100μg/mL Streptomycin, and 50μM β-2-
mercaptoethanol) overnight, before multiparameter staining.  
Fluorescence immunohistochemistry  
Pancreatic tissues were frozen in optimal cutting temperature medium and sectioned at 7Pm 
thickness. For wholemounts, pancreatic islets were fixed overnight at 4qC in 1% 
paraformaldehyde (PFA). For pancreatic sections, sections were fixed in 1% PFA for 1hr at 
RT. Following fixation, tissue was permeabilised with 0.2% triton-x100 and blocked with 5% 
FBS before the addition of a rat anti-mouse CD45 (Biolegend) and a biotinylated anti-insulin 
(Abcam; clone D6C4,) antibody mix. Secondary labelling was performed with both AlexaFluor 
633-conjugated goat anti-rat antibody (Invitrogen) and a Streptavidin-conjugated AlexaFluor 
488 antibody (Invitrogen) and mounted with VECTASHIELD mounting medium, with DAPI 
(Vector Laboratories). Islet wholemounts were centrifuged at 300g for 3mins before being 
resuspended in mounting medium, with DAPI, before mounting to the slide. All sections and 
wholemounts were imaged on Leica SP5confocal microscope.  
Image J analysis 
All analysis was performed using Fiji (Image J) (5). Islet area, perimeter, circularity, CD45 
and insulin intensity was measured by using a region of interest (ROI) on individual channels 
using Fiji’s measurement tool. Islets with insulin remaining were considered to be insulin 
containing islets (ICI) when 3 or more insulin+ beta cells were present.  
Flow Cytometry 
Cells were incubated with TruStain (anti-mouse CD16/32 [Biolegend, London, UK]) for 10min 
at 4°C, followed by fluorochrome-conjugated mAbs against cell surface markers for 30min at 
4°C. B cell phenotyping multi-parameter flow cytometry was carried out using mAbs: CD3 
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(145-2C11); B220 (RA3-6B2); CD138 (281-2); CD86 (PO3); CD80 (16-10A1); CD11c 
(N418); CD11b (M1/70); CD19 (6D5); CD44 (IM7); BAFFR (7H22-E16); MHC II (10-3-6); 
Ki67 (11F6), all purchased from Biolegend.  IL-10 (JES5-16E3); IgD (11-26c.2a); CD40 
(3/23) purchased from BD Biosciences. Galectin-1 antibody was purchased from RD systems. 
T cell phenotyping multi-parameter flow cytometry was carried out using mAbs: CD3 (145-
2C11); CD8 (53-6.7); CD4 (GK1.5); CD103 (2E7); CD69 (H1-2F3); PD-1 (29F.1A12); IFNJ 
(XMG1.2); CTLA4 (UC10-4B9); FoxP3 (MF-14), all purchased from Biolegend. CD25 
(PC61); IL-10 (JES5-16E3) were purchased from BD Biosciences. Dead cells were excluded 
from analysis by Live/Dead exclusion dye (Invitrogen, MA, USA). IFNJ; IL-10; CD107a and 
Galectin-1 were detected by intracellular cytokine staining after 3hrs of stimulation with PMA 
(50ng/ml), ionomycin (500ng/ml) and monensin (3µg/ml) [all from Sigma-Aldrich]. After 
extracellular staining, cells were fixed using fixation/permeabilization kit according to the 
manufacturer’s instructions (BD Biosciences) and subsequently stained for mAb against 
intracellular cytokines or appropriate isotype controls.  For FoxP3, CTLA4 and Ki67 staining 
cells were fixed/permeabilized using eBioscience nuclear transcription kit. Cell suspensions 
were acquired on an LSRFortessa (FACSDIVA software, BD Biosciences), and analysed using 
Flowjo software, version 10.1 (Tree Star, Oregon, USA).  
Statistical analysis 
Statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego, 
CA). Comparison between groups was determined by Mann-Whitney U test or Kolmogorov-
Smirnov test. For correlations, Pearson correlation co-efficient was calculated. Data were 
considered significant at p<0.05.  
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Data Availability  





Increased frequency of insulin-containing small pancreatic islets in naturally-protected 
NOD mice 
To investigate the features of the pancreatic islets in naturally-protected NOD mice (not 
diabetic by 30 weeks of age and hereafter referred to as protected), we used 
immunofluorescence histochemistry, including both pancreatic islet wholemounts and 
sections. First, we analysed size, by area measured in pixels/Pm, of pancreatic islets in 
wholemounts, from protected NOD mice (Fig. 1a, b). Representative images (Fig. 1a) and 
summary graph (Fig. 1b) demonstrated a range of sizes in the remaining islets in protected 
NOD mice. Next, we determined the size, by area, of pancreatic islet sections, from both 
protected and diabetic NOD mice (Fig. 1c, d). Smaller pancreatic islets were significantly more 
frequent in NOD mice that were protected from diabetes, compared to mice that had developed 
diabetes (Fig. 1d) (p<0.001). To analyse these islet data further, we used a frequency 
distribution graph to show the relative contribution, in percentage, of each islet to set ‘bins’ 
according to islet area. Islet size distribution analysis (in percentage) showed that the relative 
frequency of islets, with an area smaller than 50,000 pixels/Pm, was greater in protected (85%) 
compared with diabetic (51%) NOD mice (Fig. 1e). Further analysis in both protected and 
diabetic NOD mice revealed that insulin-containing islets (ICI) with detectable insulin-positive 
beta cells were significantly smaller in size and more frequent in the protected NOD mouse 
pancreata compared to diabetic NOD mice (p<0.01) (Fig. 1f). Interestingly, in the diabetic 
NOD mice, the very few ICI detected were larger in area (Fig. 1g). Crucially, a comparison 
between insulin-containing islets (ICI) and insulin-deficient islets (IDI), in both NOD groups, 
revealed that ICI were significantly smaller in islet area (Fig. 1h) and were more frequent (Fig. 
1i), in comparison to IDI in protected NOD mice. However, this feature was lost in diabetic 
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NOD mice with no significant difference found in islet area (Fig. 1h), or frequency (Fig.1i), in 
the few ICI identified. 
Alongside islet area, islet perimeter was also analysed and the features observed in protected 
NOD mice were further confirmed (SFig. 1a-c). In addition to islet size, we investigated 
whether islet circularity was different in protected NOD mice, compared to mice that have 
developed diabetes; however no difference was observed in total islets analysed (SFig. 1d) or 
between ICI and IDI in either the protected or diabetic NOD mouse cohort (SFig. 1e). 
Morphological characterisation of pre-diabetic NOD pancreatic islets 
Since protected mice had an increased frequency of smaller islets than diabetic mice, we 
determined if smaller islets were less affected by immune cell infiltrate when pancreatic 
insulitis was established and diabetes begins to manifest (mice aged 12-18 weeks old). 
Wholemount pancreatic islets were stained with insulin and CD45 (a marker of immune cells) 
to identify islets undergoing attack, and the size was measured by area. Figure 2a demonstrates 
heterogeneity of pancreatic islets, shown by representative pictures from two different NOD 
mice. Z-stacks taken from two individual islets are also shown in SFig. 2a. As expected, size, 
shape and quantity of the CD45 immune infiltrate were variable in each individual islet. 
However, we observed a clear pattern between size and quantity of CD45 immune infiltrate. 
We confirmed this with correlation analysis, comparing islet area (Fig. 2b) and islet perimeter 
(SFig. 2b), with fluorescence intensity of CD45 (left) and insulin (right). A significant positive 
correlation was observed (p<0.001) between islet area and CD45 immune infiltrate, alongside 
a significant negative correlation (p<0.01) between islet area and insulin+ beta cells. 
Regulatory B cells are increased in the islets of naturally-protected NOD mice 
As the pancreatic islets of naturally-protected NOD mice have considerable immune 
infiltration, although remaining normoglycemic, we analysed the B cell infiltrate to investigate 
the frequency of regulatory cells by flow cytometry (Figure 3). Firstly, we compared the 
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percentage of total B cells in groups of pooled protected NOD mice (>35 weeks), compared to 
groups of pooled younger pre-diabetic NOD mice (6-8 weeks old) (Fig. 3a, b) and observed a 
significant increase in CD19+ B cells (p<0.001). Secondly, complementing our previous 
observation that naturally-protected NOD mice have increased splenic IL-10-producing B cells 
(2), we showed a significant increase in pancreatic islet IL-10-producing B cells (Fig. 3c, SFig. 
3a). Furthermore, we also demonstrated a population of Galectin-1+ B-cells (SFig. 3b), which 
encompassed the majority of the IL-10-producing B cells and were increased in >35-week-old 
mice (p=0.06) (Fig. 3d, SFig. 3c). Interestingly, we also observed a significant increase in 
CD40+ (Fig. 3e) and CD80+ expressing B cells (Fig. 3f) (for representative gating see SFig. 
3d), both markers associated with regulatory B cell function (6; 7). It should be noted that no 
significant differences were observed in B cell expression of MHC II, CD86 or BAFFR (SFig. 
3e,f). 
Many B cells in pancreatic islets express CD138 (8; 9), a marker that identifies plasmablasts 
and plasma cells. We investigated our previously described populations identified by CD138 
and IgD expression (9), we examined these populations further (Fig. 3g-i), using markers for 
murine plasmablasts (10; 11). We assessed CD19 (Fig. 3h), CD44 and Ki67 (Fig. 3i) in each 
CD138+/- population revealing that CD138hiIgD- cells (red gate) contained a CD44hiKi67+ 
highly proliferative population which also expressed intermediate levels of CD19 (CD19int). 
With this further analysis, we propose that CD138hiIgD- cells (red gate) are a subpopulation of 
dividing plasmablasts. Few B cells that remained IgD+ were proliferating and so it is probable 
that they represent classical B cells (blue gate, CD138-IgD+) and an intermediate-stage of 
plasmablast (orange gate, CD138+IgD+). CD138+IgD- cells (grey gate) were a mixture of both 
+/- CD19 cells and increased Ki67 expression, compared to CD138-IgD+ classical B-cells, and 
are likely to represent both non-dividing intermediate-stage plasmablasts and dividing 
plasmablasts.  
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We demonstrated that protected NOD mice displayed significant increases in both 
CD138+IgD+ B cells (Fig. 3j), and CD138-IgD+ B cells (Fig. 3k), compared to young 6-8-week-
old mice. This observation indicated that CD138+IgD+ cells were not selectively recruited over 
CD138-IgD+ B-cells (Fig. 3l). However, the frequency of CD138+IgD- B-cells in both young 
and older, protected NOD mouse groups was not altered (Fig. 3m). Thus, the ratio of the 
CD138+IgD- to CD138-IgD+ B cells was increased in the younger NOD mice (Fig. 3n). This 
may suggest these B cells arrive early to the pancreatic islets. Analysis of the small population 
of dividing plasmablasts (CD138hiIgD-) showed a significant increase in protected NOD mice, 
compared to younger NOD mice (Fig. 3o). 
Enrichment of CD4+FoxP3+CTLA4+ Tregs in naturally-protected NOD mice 
To determine the characteristics of CD4+ T cells in the pancreatic islets of NOD mice, that are 
‘naturally-protected’ from diabetes, we studied the islet-infiltrating T cells of groups of pooled 
protected NOD mice by multiparameter flow cytometry, and compared these to islet-
infiltrating T cells from groups of pooled mice 6-8 weeks of age (mice with early-stage 
insulitis). CD4+ T cell frequency and expression were increased in protected NOD mice, 
although non-significant due to the variability in younger NOD mice (Fig. 4a, b). To ascertain 
if CD4+ Tregs contributed to the protection seen in protected NOD mice, we investigated the 
presence of CD4+FoxP3+ Tregs in the pancreatic islets and revealed a significant increase in 
CD4+FoxP3+ Treg cells in the pancreatic islets of protected NOD mice, compared to 6-8-week-
old mice (Fig. 4c, d). Further analysis of the CD4+FoxP3+ T cells revealed a significant increase 
in the frequency of CTLA4+CD4+FoxP3+ T cells in protected NOD mice, compared to 6-8-
week-old mice (p<0.01) (Fig. 4e, f). No significant differences were observed in the percentage 
of CD4+FoxP3+ T cells expressing CD25, PD-1 or CD103. Interestingly, intracellular cytokine 
analysis of both CD4+FoxP3-/+ T cells showed a significant increase in IFNJ-producing 
CD4+FoxP3- T cells in protected NOD mice, compared to mice aged 6-8 weeks old (Fig. 4g,h). 
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No differences in IL-10 in FoxP3+ CD4+ T cells was observed. This increase in IFNJ 
production from re-stimulated CD4+ T cells may reflect enhanced antigen experience.  
Islet CD8 TRM in naturally-protected NOD mice switch to a CD103- phenotype 
Additional analysis of T cells was performed. Similar to CD4+ T cells, CD8+ T cells were 
modestly increased in frequency in >35-week-old mice (Fig.5a,b). As CD8+ T cells are found 
from an early age in the pancreatic tissue we investigated markers of tissue residency. CD8+ 
tissue resident memory cells (TRM) can be distinguished by the surface markers CD69 and 
CD103 (12). CD8+ TRM populations have now been widely studied in various tissues and play 
a crucial role in immunosurveillance and protect against secondary viral infections (13). We 
demonstrated 3 key populations of CD8+ T cells in the pancreas of NOD mice: CD103-CD69- 
recirculating cells; CD103-CD69+ TRM and CD103+CD69+ TRM (Fig. 5d-g). Protected >35-
week-old NOD mice and younger NOD mice had similar frequencies of recirculating 
CD8+CD103-CD69- T cells (Fig. 5d). Strikingly, CD8+ TRM cells were significantly different 
between protected NOD mice and mice aged 6-8 weeks old, with a shift towards greater 
prominence of CD103- TRM cells in protected NOD mice (Fig. 5e, f). Further, both CD8+ 
CD103-/+ TRM populations expressed  CD107a, IFNJ and PD-1, with the CD103- TRM becoming 
more activated overall, after stimulation (Fig. 5g). There was no enrichment of PD-1 (a marker 
for T cell exhaustion (14) in either TRM population (Fig. 5g). Further analysis of the CD107a+ 
cells (a marker for recent degranulation) in the TRM populations, revealed CD107a+CD103+ 
TRM cells had fewer IFNJ+PD-1- expressing cells than the CD107a+CD103- TRM (P<0.05) (Fig. 
4i, summary graph), but overall a greater proportion of PD-1 expression (Fig. 4h, pie charts). 
Evaluation of IFNJ and PD-1 sub-populations in the younger as well as protected NOD mice 
showed a significant increase in IFNJ+PD-1+ T cells in both CD103+/- TRM populations (Fig. 
4j, k). Overall, naturally protected NOD mice show a shift towards a CD8+CD103- TRM 
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population, which has a more activated phenotype after stimulation, alongside an increase in 
IFNJ in the TRM subsets.
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Discussion 
In this report, we demonstrate key characteristics of pancreatic islets in a group of mice that 
are naturally protected from developing spontaneous diabetes. Firstly, we discovered that 
smaller islets remain in these protected mice, with a clear correlation between islet size and 
immune infiltrate. Furthermore, insulin+ beta cells are still present in pancreatic islets despite 
florid immune infiltrate. This immune infiltrate has a high frequency of B and T cells, however 
the compositional signature was notably different in both immune cell compartments. 
For the first time, we show that protected NOD mice have an increased frequency of smaller 
islets remaining in the pancreas, with insulin-containing islets smaller in size compared to islets 
deficient in insulin+ beta cells. NOD mice that developed diabetes did not display this pattern. 
Moreover, we show in pre-diabetic NOD mice, larger islets have larger immune infiltrates. 
Previously, islet size has been shown to decrease as the duration of disease progresses in the 
NOD mouse (15); however more sophisticated imaging identified that the smaller islets, 
located peripherally, are destroyed earlier in the disease process (16). However, surprisingly, 
the CD3+ immune infiltrate was not localized to the smaller islets or within a particular islet 
region (16). In humans, individuals with recent-onset type 1 diabetes have larger islets 
compared with people with long standing type 1 diabetes (17).  
Islets smaller in size than those found in the 12-16 week old NOD mice may have been 
destroyed; however we noted that islet size and infiltrate were correlated, but curiously the very 
few remaining islets with insulin+ beta cells were not smaller in size. Certainly, no correlation 
between beta-cell mass and insulitis was observed in human pancreatic sections from donors 
with type 1 diabetes, but islet size was not addressed (18). This dichotomy requires further 
study to ascertain why this is the case. An explanation for this correlation between islet size 
and immune infiltrate could be explained by an increased capillary density (19), providing 
more immune cell access.  
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IL-10-producing B cells (B10 cells) diminish the inflammatory response (20). Building on 
previous work (2), we now show that naturally-protected NOD mice have a regulatory B cell 
bias in the pancreatic islets. We demonstrate Galectin-1+ B cells in pancreatic islets, a marker 
shown to be necessary for the function of regulatory B cells (21), and production of this protein, 
from activated B cells, can influence T cell responses, including inducing T cell apoptosis (22). 
Furthermore, the infiltrating B cells have increased levels of other cell surface markers 
associated with regulation. Firstly, the CD80 molecule is known to preferentially bind CTLA4 
(23), which we also find significantly increased on CD4+FoxP3+ Tregs in these protected NOD 
islets. Secondly, B10 cells require CD40 in order to suppress effector T cells and autoimmunity 
(6). Interestingly, here we describe a significant increase in dividing CD138hiCD44hi 
plasmablasts in protected NOD mice, previously reported to be an IL-10-producing population 
(10).  
We observed that CD138+IgD- pancreatic islet B cells are similar in frequency in both younger 
and protected NOD mice. Early islet B cells have a B1 B cell phenotype (24), B cells that are 
preferentially located in the peritoneum and pleural cavities, and are players in the initiation of 
type 1 diabetes (25). CD138+IgD- cells identified here are a heterogenous pool of dividing and 
non-dividing plasmablasts at various intermediate differentiation stages, which consist of 
CD19+ and CD19- cells which lack IgM expression and are more proliferative compared to 
classical B cells. Crucially, this subset also contains antigen-specific B cells (9). Further work 
on these defined subsets is required to understand if they are a B1-like-cell that has altered due 
to the inflamed tissue environment. 
Lastly, we identified a significant shift in the CD8+ T cell compartment. A CD8+CD103+TRM 
phenotype is more prevalent in the younger NOD, whereas a CD8+CD103- TRM phenotype 
dominates in the protected NOD mice, with CD8+CD103- TRM cells producing increased IFNJ, 
when re-stimulated ex vivo. CD8+ TRM respond rapidly to control local immune responses in 
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the tissue and so are central in tissue immunosurveillance. CD8+CD103- TRM have been 
described in various tissues, with CD8+CD103+ TRM cells located preferentially in the 
epidermis while CD8+CD103- TRM cells are located in the dermis of human skin (26), with 
distinct functional roles (26; 27). CD8+CD103+/- TRM have been defined as separate 
populations, with different patterns of recall, molecular signature and migration (27-29). 
CD8+CD103- TRM are more transient in the tissue compared to CD103+ counterparts (28), 
alongside an increased expression of sphingosine-1-phosphate receptor-1 (S1P1R) (27). It 
remains unclear if the enrichment of the CD8+CD103- TRM population in the older protected 
mice represents a more transient CD8 TRM population, and this would require further 
interrogation. CD8+ TRM in human pancreatic tissue from adults with recent onset type 1 
diabetes have been identified, but interestingly, only CD8+CD103+ TRM cells were detected in 
pancreatic tissue (30). However, in non-diabetic donors a CD8+CD103- TRM phenotype has 
been observed in approximately 20-30% of resident CD8+ T cells in pancreatic islets (31).  
E-cadherin, the principal ligand for CD103, is expressed by pancreatic islets (32) and this 
interaction can result in the release of cytokines and lytic granules from CD8+ T cells, therefore 
controlling cytotoxic CD8+T cell responses (33; 34). CD103 is also required for the efficient 
destruction of pancreatic islet allografts (35). A shift towards CD8+ T cells lacking CD103 in 
naturally-protected NOD mice may result in reduced targeted cell death. However, this CD103- 
TRM shift may also be as a result from the loss of the ligand E-cadherin due to substantial loss 
of pancreatic islets. 
In conclusion, naturally-protected NOD mice have a unique pancreatic signature, with 
remaining islets that contain smaller insulin-producing beta cells and an immune infiltrate (both 
T and B cells) shifted towards a regulatory phenotype. These results are important to 
understand the balance between a destroyed islet and an islet that remains, even partially, intact. 
Limitations in this study reflect the difficulty of studying both heterogenous islets and immune 
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cell subsets, especially with limited cell numbers. Furthermore, protected NOD mice represent 
a pool of mice that cannot be detected early in the disease process and so comparisons with 
mice that are younger, including mice that have established insulitis, is challenging. These 
younger mice would encompass both mice that will develop diabetes and be naturally 
protected, and we cannot, as yet, predict which mice will develop diabetes and distinguish them 
from mice that will be spared. Nevertheless, these observations highlight the need for further 
investigation into the dynamic process of beta-cell destruction. 
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Figure 1. Pancreatic islets from naturally-protected NOD mice are smaller in size. Pancreatic 
islet wholemounts and sections from naturally-protected NOD mice (>35 weeks old; blue) and 
NOD mice that had developed diabetes (grey) were analysed by immunofluorescence staining 
for CD45 (yellow), insulin (red) and DAPI (blue). (a) Representative images of wholemounts 
from naturally protected >35-week-old mice; (b) graph showing distribution of individual islet 
area in >35-week-old mice; (c) representative images from pancreatic sections from >35-week-
old mice and mice that have developed diabetes; (d) Summary graphs of islet area from 
individual islets in >35-week-old and diabetic NOD mice (left) and (e) the relative frequency 
distribution in percentage (right) of pancreatic islets; (f) summary graphs for insulin containing 
islets (ICI) in both >35-week-old and diabetic NOD mice showing area, (g) frequency 
distribution in number of islets (left), relative frequency distribution in percentage (right); (h) 
summary graphs for insulin-containing islets (ICI) and insulin-deficient islets (IDI) from >35-
week-old and diabetic NOD mice showing islet area (left); (i) relative frequency distribution 
of percentage of these islets in mice diabetic NOD mice (left), and relative frequency 
distribution of percentage of these islets in >35-week-old NOD (right). Data shown are from 
at least 2 independent experiments (protected n=3; diabetic n=3). *<0.05; **<0.01; ***<0.001; 
Kolmogorov-Smirnov test. 
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Figure 2. Morphological characterisation of pre-diabetic NOD pancreatic islets. Pancreatic 
islet wholemounts from NOD mice aged 12-18 weeks were analysed by immunofluorescence 
staining for the immune cell marker CD45 (yellow) and beta cell marker insulin (red). (a) 
Representative images from 2 (top panel, bottom panel) individual NOD mice, 8 pancreatic 
islets shown for each individual NOD mouse. (b) Correlative graphs for both CD45 and insulin 
expression against islet area. Data are from 4 independent experiments, n=8.  
Figure 3. Naturally-protected NOD mice have increased regulatory B cells in the pancreatic 
islet infiltrate. 
Pancreata from groups (n=2-3) of NOD mice aged 6-8 weeks old (younger prediabetic; red) 
and >35 weeks old (protected; blue) were taken and pancreatic islets pooled together before 
flow cytometric analysis. (a) Representative histograms to show CD19+ B cell expression; (b) 
Overall percentages for CD19+ B cells; (c-f) Overall percentages of CD19+ B cells expressing 
(c) IL-10, (d) IL-10+ in Gal-1+ and Gal-1- compartments, (e) CD80 (f) CD40; (g-i) 
representative flow cytometry plots gated on live, CD3-CD11b-CD11c- cells for (g) CD138 and 
IgD populations; CD138-IgD+ (blue gate); CD138+IgD+ (orange gate); CD138+IgD- (grey 
gate), CD138hiIgD- (red gate); (h) CD19 expression on each of the CD138/IgD populations; (i) 
histograms showing CD44 (left) and Ki67 (right) on each of the CD138/IgD populations; (j, 
k); Overall percentages for (j) CD138+IgD+ cells (k) CD138-IgD+; (l) Ratio of CD138+IgD+ to 
CD138-IgD+ B cells; (m) Overall percentages of CD138+IgD- cells; (n) Ratio of CD138+IgD- 
cells to CD138-IgD+ B cells (o) Summary graph for percentages of CD138hiIgD- plasmablasts 
in both young NOD and protected >35-week-old NOD mouse groups. Data shown are from at 
least 4 independent experiments. *<0.05; **<0.01; ***<0.001, Mann-Whitney U test. 
Figure 4. Increased frequency of CD4+CTLA4+FoxP3+ Tregs in naturally-protected NOD 
mice. Pancreata from groups (n=2-3) of NOD mice aged >35 weeks old (protected; blue) and 
6-8 weeks old (younger prediabetic; red) were taken and pancreatic islets pooled together 
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before flow cytometric analysis. (a) representative histogram of CD4 expression; (b) CD4+ T 
cell percentages (left) and CD4 geometric mean fluorescence intensity (GMFI) (right); (c) 
CD4+FoxP3+ T cell expression representative histograms and (d) summary graph; (e, f) 
expression of CD4+ Treg markers on CD4+FoxP3+ and CD4+FoxP3- T cells with (e) 
demonstrating representative histograms for CTLA4, CD25, PD-1 and CD103 and (f) graphs 
showing summary percentages; (g, h) IFNJ and IL-10 expression in CD4+FoxP3+/- subsets, 
with (g) illustrating representative flow plots and (h) summary graphs. Cells were gated on 
singlets, live, CD4+ cells. Data are from at least 3 independent experiments. *<0.05; **<0.01, 
Mann-Whitney U test. 
Figure 5. CD8+ TRM in naturally-protected NOD mice switch to a CD103- phenotype. 
Pancreatic islets from groups (n=2-3) of NOD mice aged >35 weeks old (protected; blue) and 
6-8 weeks old (younger prediabetic; red) were taken and pancreatic islets pooled together, 
before flow cytometric analysis. (a) representative flow plots showing CD8+ T cells; (b) CD8+ 
T cell percentages; (c) representative flow plots to show CD103-CD69- recirculating CD8+ T 
cells and CD103+/-CD69+ TRM cells (d-g) percentages CD8+ T cell populations with (d) 
demonstrating CD103-CD69- recirculating T cells, (e) CD103-CD69+ TRM, (f) CD103+CD69+ 
TRM and (g) pie charts summarising total percentages of CD107a, IFNJ and PD-1 expression 
on both CD103+/- TRM CD8+ subsets; (h, i) CD8+CD103+/- TRM subset analysis gated on 
CD107+ cells containing IFNJ+PD-1-; IFNJ+PD-1+ and IFNJ-PD-1+ subsets with (h) showing 
overall percentages of IFNJ and PD-1 populations and (i) illustrating pie charts showing 
proportion of CD107a-expressing cells for IFNJ and PD-1 populations (j, k) IFNJ+ and PD-1+ 
populations on the CD107a+ subset of CD8+CD103-CD69+ TRM (top) and CD8+CD103+CD69+ 
TRM (bottom) from 6-8-week-old (red) and >35-week-old (blue) NOD mice (j) representative 
flow cytometry plots (k) summary graphs of percentages. Cells were gated on singlets, live, 
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CD8+ cells. Data are from at least 3 independent experiments. *<0.05; **<0.01; ***<0.001, 
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